Cargando…

Hypothesizing that a Pro-Dopaminergic Regulator (KB220z(™) Liquid Variant) can Induce “Dopamine Homeostasis” and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence

In order to explore the initiation of detoxification of addictive patients to opiates/opioids (along with some other anti-withdrawal agents), we developed a protocol to be utilized in treatment centers particularly with heavily dependent opiate/opioid subjects. Out of 17 subjects, only three receive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blum, Kenneth, Whitney, Debra, Fried, Lye, Febo, Marcelo, Waite, Roger L, Braverman, Eric R, Dushaj, Kristina, Li, Mona, Giordano, John, Demetrovics, Zsolt, Badgaiyan, Rajendra D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638455/ https://www.ncbi.nlm.nih.gov/pubmed/29034323 http://dx.doi.org/10.23937/2378-3656/1410125

Ejemplares similares

Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2017)

Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term
por: Blum, Kenneth, et al.
Publicado: (2016)

“Pro-dopamine regulation (KB220Z™)” as a long-term therapeutic modality to overcome reduced resting state dopamine tone in opiate/opioid epidemic in America
por: Blum, K, et al.
Publicado: (2016)

Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake
por: Duquette, Lucien L, et al.
Publicado: (2016)

KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?
por: McLaughlin, Thomas, et al.
Publicado: (2016)

Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality
por: Blum, Kenneth, et al.
Publicado: (2015)

Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction
por: Blum, Kenneth, et al.
Publicado: (2015)

Lyme and Dopaminergic Function: Hypothesizing Reduced Reward Deficiency Symptomatology by Regulating Dopamine Transmission
por: Blum, Kenneth, et al.
Publicado: (2017)

Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD
por: McLaughlin, Thomas, et al.
Publicado: (2018)

Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z
por: Febo, Marcelo, et al.
Publicado: (2017)

Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape
por: Blum, Kenneth, et al.
Publicado: (2017)

Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms
por: Blum, Kenneth, et al.
Publicado: (2015)

CLONIDINE IN OPIATE DETOXIFICATION
por: Gangadhar, B.N., et al.
Publicado: (1982)

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)
por: Kenneth, Blum, et al.
Publicado: (2018)

Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual
por: Blum, Kenneth, et al.
Publicado: (2020)

Using the Neuroadaptagen KB200z™ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis
por: McLaughlin, Thomas, et al.
Publicado: (2015)

NON COMPLETERS OF OPIATE DETOXIFICATION PROGRAM
por: Nigam, A.K., et al.
Publicado: (1992)

Enhancing Brain Pregnenolone May Protect Cannabis Intoxication but Should Not Be Considered as an Anti-addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti-Reward
por: Blum, Kenneth, et al.
Publicado: (2015)

Pilot clinical observations between food and drug seeking derived from fifty cases attending an eating disorder clinic
por: Beitscher-Campbell, Harriet, et al.
Publicado: (2016)

Craving by imagery cue reactivity in opiate dependence following detoxification
por: Behera, Debakanta, et al.
Publicado: (2003)

Evidence of Dopaminergic Processing of Executive Inhibition
por: Badgaiyan, Rajendra D., et al.
Publicado: (2011)

Six-Month Follow-Up Study of Ultrarapid Opiate Detoxification With Naltrexone
por: Forozeshfard, Mohammad, et al.
Publicado: (2014)

Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone?
por: McLaughlin, Thomas, et al.
Publicado: (2017)

NIDA-Drug Addiction Treatment Outcome Study (DATOS) Relapse as a Function of Spirituality/Religiosity
por: Schoenthaler, Stephen J., et al.
Publicado: (2015)

A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain
por: Blum, Kenneth, et al.
Publicado: (2014)

Putative Dopamine Agonist (KB220Z) Attenuates Lucid Nightmares in PTSD Patients: Role of Enhanced Brain Reward Functional Connectivity and Homeostasis Redeeming Joy
por: McLaughlin, Thomas, et al.
Publicado: (2015)

Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
por: Ceccanti, Mauro, et al.
Publicado: (2022)

Buprenorphine versus dihydrocodeine for opiate detoxification in primary care: a randomised controlled trial
por: Wright, Nat MJ, et al.
Publicado: (2007)

The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification
por: Sheard, Laura, et al.
Publicado: (2009)

Anesthesia-assisted opiate detoxification (AAOD) for heroine addicts during 24-hour ICU admission: complications and results for opiate abstinence at 1-year follow-up
por: de Jong, C
Publicado: (2004)

Evoked Potentials and Memory/Cognition Tests Validate Brain Atrophy as Measured by 3T MRI (NeuroQuant) in Cognitively Impaired Patients
por: Braverman, Eric R., et al.
Publicado: (2015)

Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
por: Blum, Kenneth, et al.
Publicado: (2021)

The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification
por: Sheard, Laura, et al.
Publicado: (2009)

Hypothesizing Las Vegas and Sutherland Springs Mass Shooters Suffer from Reward Deficiency Syndrome: “Born Bad”
por: McLaughlin, Thomas, et al.
Publicado: (2017)

The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project pilot study: protocol for a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification
por: Sheard, Laura, et al.
Publicado: (2007)

Ascorbic Acid Inhibits Development of Tolerance and Dependence to Opiates in Mice: Possible Glutamatergic or Dopaminergic Modulation
por: Kulkarni, S. K., et al.
Publicado: (2008)

Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of “Dopamine Homeostasis”
por: Blum, Kenneth, et al.
Publicado: (2022)

Hypothesizing High Negative Emotionality as a Function of Genetic Addiction Risk Severity (GARS) Testing in Alcohol Use Disorder (AUD)
por: Blum, Kenneth, et al.
Publicado: (2020)

CompTIA A+: exams A+ essentials (220-601), 220-602, 220-603, 220-604
por: Brooks, Charles J, et al.
Publicado: (2008)

Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors
por: Gupta, Ashim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h1q952maukc4poamgqkpnorn4h